EG110A for Neurogenic Detrusor Overactivity
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a first-in-human, Phase 1b/2a, open-label, dose-escalation study of a single treatment course consisting of multiple intradetrusor injections of EG110A in male and female adult participants with Neurogenic Detrusor Overactivity (NDO)-related incontinence following Spinal Cord Injury (SCI), who have persistent incontinence after standard of care therapy and who perform Clear Intermittent Catheterization (CIC) on a regular basis.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, it seems that participants should have been on a stable treatment for Neurogenic Detrusor Overactivity for at least 3 months before joining the trial.
What safety data exists for EG110A in treating neurogenic detrusor overactivity?
What data supports the effectiveness of the drug EG110A for treating neurogenic detrusor overactivity?
Who Is on the Research Team?
Cornelia Haag-Molkenteller, MD
Principal Investigator
EG 427
Are You a Good Fit for This Trial?
This trial is for adults with bladder control issues due to nerve damage from a spinal cord injury, who still have incontinence despite standard treatments and regularly use a catheter. Participants must be stable post-injury and able to attend all study visits.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single treatment course consisting of multiple intradetrusor injections of EG110A
Follow-up
Participants are monitored for safety and effectiveness after treatment, including urodynamic assessments and bladder diary evaluations
What Are the Treatments Tested in This Trial?
Interventions
- EG110A
Find a Clinic Near You
Who Is Running the Clinical Trial?
EG 427
Lead Sponsor